Back to Search
Start Over
Preclinical Safety Evaluation of Oncolytic Herpes Simplex Virus Type 2.
- Source :
-
Human Gene Therapy . May2019, Vol. 30 Issue 5, p651-660. 10p. - Publication Year :
- 2019
-
Abstract
- Oncolytic virotherapy is a new and safe therapeutic strategy based on the inherent cytotoxicity of oncolytic viruses and their ability to replicate and spread within tumors in a selective manner. In a previous study, a new type of oncolytic herpes simplex virus type 2 (oHSV-2, named OH2) was constructed to treat human cancers. That study demonstrated that OH2 is genetically and biologically stable. Its antitumor activity was maintained, even after passaging the virus for >20 generations. To advance OH2 into a clinical trial, a systematic preclinical safety evaluation was performed, which included: an acute toxicity test of OH2 in BALB/c mice; repeated dose toxicity tests of OH2 in BALB/c mice and cynomolgus monkeys; and biodistribution assays of OH2 in BALB/c mice, tumor-bearing mice, tumor-bearing nude mice, and cynomolgus monkeys. The results of this preclinical safety evaluation of OH2 indicate that OH2 is safe and suitable for clinical trials. [ABSTRACT FROM AUTHOR]
- Subjects :
- *HERPES simplex virus
*ACUTE toxicity testing
*KRA
*TOXICITY testing
Subjects
Details
- Language :
- English
- ISSN :
- 10430342
- Volume :
- 30
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Human Gene Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 136501162
- Full Text :
- https://doi.org/10.1089/hum.2018.170